WO2002062803A1 - Thienopyrimidine derivative - Google Patents

Thienopyrimidine derivative Download PDF

Info

Publication number
WO2002062803A1
WO2002062803A1 PCT/JP2002/001008 JP0201008W WO02062803A1 WO 2002062803 A1 WO2002062803 A1 WO 2002062803A1 JP 0201008 W JP0201008 W JP 0201008W WO 02062803 A1 WO02062803 A1 WO 02062803A1
Authority
WO
WIPO (PCT)
Prior art keywords
thienopyrimidine derivative
derivative
thienopyrimidine
medicine
salt
Prior art date
Application number
PCT/JP2002/001008
Other languages
French (fr)
Japanese (ja)
Inventor
Hirotsune Itahana
Takashi Kamikubo
Eisuke Nozawa
Hidetaka Kaku
Masamichi Okada
Takashi Toya
Atsushi Nakamura
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Publication of WO2002062803A1 publication Critical patent/WO2002062803A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A novel thienopyrimidine derivative or a salt thereof. The compound has metabotropic glutamate receptor activity and is useful as a medicine.
PCT/JP2002/001008 2001-02-08 2002-02-07 Thienopyrimidine derivative WO2002062803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-32121 2001-02-08
JP2001032121 2001-02-08

Publications (1)

Publication Number Publication Date
WO2002062803A1 true WO2002062803A1 (en) 2002-08-15

Family

ID=18896101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001008 WO2002062803A1 (en) 2001-02-08 2002-02-07 Thienopyrimidine derivative

Country Status (1)

Country Link
WO (1) WO2002062803A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029060A1 (en) * 2002-09-26 2004-04-08 Nihon Nohyaku Co., Ltd. Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
WO2007024593A1 (en) * 2005-08-19 2007-03-01 Schering Corporation Fused tricyclic mglur1 antagonists as therapeutic agents
WO2007072090A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Thienopyridine derivatives as modulators of metabotropic glutamate receptors
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
US7939657B2 (en) * 2003-10-29 2011-05-10 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US8691833B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
WO2015056771A1 (en) 2013-10-17 2015-04-23 アステラス製薬株式会社 Sulfur-containing bicyclic compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
JPH11189596A (en) * 1997-12-25 1999-07-13 Yamanouchi Pharmaceut Co Ltd Metabotropic glutamate receptor agonist and new imidazobenzothiazole derivative
WO2000059913A1 (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzimidazole derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
JPH11189596A (en) * 1997-12-25 1999-07-13 Yamanouchi Pharmaceut Co Ltd Metabotropic glutamate receptor agonist and new imidazobenzothiazole derivative
WO2000059913A1 (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzimidazole derivatives

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029060A1 (en) * 2002-09-26 2004-04-08 Nihon Nohyaku Co., Ltd. Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof
US7939657B2 (en) * 2003-10-29 2011-05-10 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
US7989464B2 (en) 2004-06-15 2011-08-02 Schering Corporation mGluR1 antagonists as therapeutic agents
US7485648B2 (en) 2004-06-15 2009-02-03 Schering Corporation mGluR1 antagonists as therapeutic agents
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2007024593A1 (en) * 2005-08-19 2007-03-01 Schering Corporation Fused tricyclic mglur1 antagonists as therapeutic agents
US7767815B2 (en) 2005-08-19 2010-08-03 Schering Corporation Fused tricyclic mGluR1 antagonists as therapeutic agents
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
WO2007072090A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Thienopyridine derivatives as modulators of metabotropic glutamate receptors
US8691833B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8691831B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
WO2015056771A1 (en) 2013-10-17 2015-04-23 アステラス製薬株式会社 Sulfur-containing bicyclic compound
US9051339B2 (en) 2013-10-17 2015-06-09 Astellas Pharma Inc. Sulfur-containing bicyclic compound
CN105636965A (en) * 2013-10-17 2016-06-01 安斯泰来制药株式会社 Sulfur-containing bicyclic compound
KR20160071408A (en) 2013-10-17 2016-06-21 아스텔라스세이야쿠 가부시키가이샤 Sulfur-containing bicyclic compound
US9642852B2 (en) 2013-10-17 2017-05-09 Astellas Pharma Inc. Sulfur-containing bicyclic compound
CN105636965B (en) * 2013-10-17 2017-11-24 安斯泰来制药株式会社 The ring type compound of sulfur-bearing two
EA029075B1 (en) * 2013-10-17 2018-02-28 Астеллас Фарма Инк. Sulfur-containing bicyclic compound

Similar Documents

Publication Publication Date Title
EP1453512B8 (en) Acetylene derivatives having mglur 5 antagonistic activity
AU2003227360A1 (en) Novel amide derivatives or salts thereof
AU2002349777A1 (en) Novel benzophenone derivatives or salts thereof
AU2002365647A1 (en) Pyridyloxyalkanoic acid amide derivatives useful as fungicides
AU2002243508A1 (en) Alpha-aminoboronic acids prepared by novel synthetic methods
AU2003214154A1 (en) Velocity responsive time tracking
WO2002062803A1 (en) Thienopyrimidine derivative
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
AU2003213185A1 (en) Arylsulfone derivatives
WO2002060906A3 (en) Crystal modification of olanzapine
AU2003217214A1 (en) The use of sulfonated compounds as a barrier contraceptive
AU1782201A (en) 2786, a novel human aminopeptidase
AU1877399A (en) Bicyclene substituted by an aminocarbonyl radical, the production and use thereof as a medicament
AU2003232785A1 (en) Novel anthracene derivatives and the use thereof as a medicament
AU3382001A (en) Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
WO2003045320A3 (en) Somatostatin analog and uses thereof
AU2002339693A1 (en) A process for the preparation of polyaniline salt
AU2003224149A1 (en) N'-cyano-n-methyl-imidamide derivatives
AU2003232698A1 (en) Use of a n,n'-dibenzyl-thiourea as medicine
AU2002233181A1 (en) Novel, 2,5-diazabicyclo[2.2.1]heptane derivatives
AU2003250090A1 (en) 2,4-dihydroxybenzoic acid derivatives
AU2002366040A1 (en) Novel tetronic acid derivative
AU2003255737A1 (en) Antimicrobial 2, 4-diamino-pteridine derivatives
AU2002357226A1 (en) The total synthesis of merrilactone a
AU2002348685A1 (en) 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP